Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1233 results
September 2018
-
Press Release
World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research[1] 79% are willing… -
Press Release
Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
Alcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos,… -
Press Release
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients
Real-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th… -
Press Release
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS
Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects… -
Press Release
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no… -
Press Release
Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz
Der globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg… -
Press Release
Alcon confirme son engagement envers la Suisse en perspective de la scission proposée avec Novartis
Le siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon… -
Press Release
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has… -
Key Release
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
August 2018
-
Press Release
European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma… -
Key Release
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising… -
Press Release
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…